4.5 Article

A novel genetic locus modulates infarct volume independently of the extent of collateral circulation

期刊

PHYSIOLOGICAL GENOMICS
卷 45, 期 17, 页码 751-763

出版社

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/physiolgenomics.00063.2013

关键词

ischemic stroke; collateral circulation; quantitative trait locus; transgressive segregation; stroke genetics

资金

  1. National Heart, Lung, and Blood Institute [1R01 HL-097281]
  2. American Heart Association [0815132E]

向作者/读者索取更多资源

In the mouse model of permanent, middle cerebral artery occlusion, infarct volume varies widely across inbred strains but generally is inversely correlated with collateral vessel number. However, we also observed certain mouse strains that share similar collateral vessel anatomy but exhibit significantly different infarct volume. To identify genetic factors determining infarct volume in a collateral vessel-independent manner, we performed quantitative trait locus analysis on a F2 cross between C57BL/6J and C3H/HeJ strains. We mapped four novel loci (Civq4 through Civq7) that modulate infarct volume. Civq4, on chromosome 8, is the strongest locus (logarithm of the odds 9.8) that contributes 21% of the phenotypic variance of infarct volume in the cross. The Civq4 and Civq6 loci represent transgressive B6 alleles that render animals susceptible to larger infarcts. Based on genomic sequence and microarray analyses, we propose candidate genes for the Civq4 locus. By selecting inbred strains with similar collateral vessel anatomy but that vary significantly in infarct volume, we have mapped four loci determining infarct volume in a mouse model of ischemic stroke. Two of the loci appear to modulate infarct volume through a collateral vessel-independent mechanism. Based on strain-specific sequence variants and differences in transcript levels, Msr1 and Mtmr7 appear to be strong candidate genes for Civq4. Identifying the underlying genetic factors of these loci will elucidate the genetic architecture response to cerebral ischemia, shed new light on disease mechanisms of ischemic stroke, and identify potential therapeutic targets for clinical applications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Genetics & Heredity

Predictors of mortality in patients with hereditary hemorrhagic telangiectasia

K. P. Thompson, J. Nelson, H. Kim, L. Pawlikowska, D. A. Marchuk, M. T. Lawton, Marie E. Faughnan

Summary: Chronic gastrointestinal bleeding, anemia, and symptomatic liver vascular malformations are associated with increased mortality in HHT patients, while pulmonary arteriovenous malformations and brain vascular malformations do not seem to impact mortality.

ORPHANET JOURNAL OF RARE DISEASES (2021)

Article Medicine, Research & Experimental

Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

Wenqing Li, Robert Shenkar, Mathew R. Detter, Thomas Moore, Christian Benavides, Rhonda Lightle, Romuald Girard, Nicholas Hobson, Ying Cao, Yan Li, Erin Griffin, Carol Gallione, Joseph M. Zabramski, Mark H. Ginsberg, Douglas A. Marchuk, Issam A. Awad

Summary: Propranolol, a pleiotropic beta-adrenergic blocker, has shown promising results in reducing cerebral cavernous malformations in animal models such as zebrafish and mice, possibly due to its beta 1 adrenergic antagonism. These findings suggest that propranolol or other beta 1-selective antagonists may be beneficial in treating CCM disease.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Article Clinical Neurology

Multicenter Research Data of Epilepsy Management in Patients With Sturge-Weber Syndrome

Lindsay F. Smegal, Alison J. Sebold, Adrienne M. Hammill, Csaba Juhasz, Warren D. Lo, Daniel K. Miles, Angus A. Wilfong, Alex Levin, Brian Fisher, Karen L. Ball, Anna L. Pinto, Anne M. Comi

Summary: The study analyzed the use of neurological drug treatment in SWS patients across different demographic and SWS characteristic groups. Results showed that variables such as sex, ethnicity, and brain, skin, and eye involvement can impact medication use. The study also found that a history of neurosurgery, bilateral brain involvement, and family history may affect the number of antiseizure medications used by patients.

PEDIATRIC NEUROLOGY (2021)

Article Multidisciplinary Sciences

PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism

Aileen A. Ren, Daniel A. Snellings, Yourong S. Su, Courtney C. Hong, Marco Castro, Alan T. Tang, Matthew R. Detter, Nicholas Hobson, Romuald Girard, Sharbel Romanos, Rhonda Lightle, Thomas Moore, Robert Shenkar, Christian Benavides, M. Makenzie Beaman, Helge Mueller-Fielitz, Mei Chen, Patricia Mericko, Jisheng Yang, Derek C. Sung, Michael T. Lawton, J. Michael Ruppert, Markus Schwaninger, Jakob Koerbelin, Michael Potente, Issam A. Awad, Douglas A. Marchuk, Mark L. Kahn

Summary: Vascular malformations are caused by increased signaling through the PI3K-mTOR pathway and loss of function of the CCM complex, which are found in the majority of human CCMs. Using mouse models, researchers discovered that the formation of CCMs can be effectively blocked by the mTORC1 inhibitor rapamycin.

NATURE (2021)

Article Clinical Neurology

Cyclo-oxygenase 2, a putative mediator of vessel remodeling, is expressed in the brain AVM vessels and associates with inflammation

Sara Keranen, Santeri Suutarinen, Rahul Mallick, Johanna P. Laakkonen, Diana Guo, Ludmila Pawlikowska, Behnam Rezai Jahromi, Tuomas Rauramaa, Seppo Yla-Herttuala, Doug Marchuk, Timo Krings, Timo Koivisto, Michael Lawton, Ivan Radovanovic, Helen Kim, Marie E. Faughnan, Juhana Frosen

Summary: COX2 expression is found in the majority of bAVMs and is associated with inflammation, but not hemorrhage. Further studies are needed to understand the role of COX2 signaling in the pathobiology and clinical course of bAVMs.

ACTA NEUROCHIRURGICA (2021)

Article Peripheral Vascular Disease

A novel somatic mutation in GNAQ in a capillary malformation provides insight into molecular pathogenesis

F. Galeffi, D. A. Snellings, S. E. Wetzel-Strong, N. Kastelic, J. Bullock, C. J. Gallione, P. E. North, D. A. Marchuk

Summary: Sturge-Weber syndrome (SWS) is a rare neuro-cutaneous disorder caused by GNAQ gene mutations. A new Q209R mutation was identified, which may contribute to signal activation but is less common. Additionally, different GNAQ mutations exhibit varying levels of activation but have similar downstream effects.

ANGIOGENESIS (2022)

Article Genetics & Heredity

Genetic genealogy uncovers a founder deletion mutation in the cerebral cavernous malformations 2 gene

Carol J. Gallione, Matthew R. Detter, Adrienne Sheline, Henrietta M. Christmas, Cornelia Lee, Douglas A. Marchuk

Summary: Cerebral cavernous malformations (CCM) are vascular malformations that can occur sporadically or be inherited. This study found that a gene deletion mutation in seemingly unrelated patients may have originated from a founder mutation that occurred centuries ago on the North American continent. Further investigation is needed for the inclusion of another gene, NACAD, in this deletion for these patients.

HUMAN GENETICS (2022)

Letter Medicine, Research & Experimental

Propranolol as therapy for cerebral cavernous malformations: a cautionary note

Robert Shenkar, Thomas Moore, Christian Benavides, Rhonda Lightle, Matthew R. Detter, Nicholas Hobson, Romuald Girard, Dorothy DeBiasse, Mary Patrucco, Carol Gallione, Joseph M. Zabramski, Douglas A. Marchuk, Issam A. Awad

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Article Multidisciplinary Sciences

Quantification metrics for telangiectasia using optical coherence tomography

Jillian L. Cardinell, Joel M. Ramjist, Chaoliang Chen, Weisong Shi, Nhu Q. Nguyen, Tiffany Yeretsian, Matthew Choi, David Chen, Dewi S. Clark, Anne Curtis, Helen Kim, Marie E. Faughnan, Victor X. D. Yang

Summary: This study utilizes optical coherence tomography (OCT) to image and quantitatively characterize dermal HHT lesions in order to understand the dynamic processes of the disease. Refined metrics specifically tailored for HHT were developed based on a pilot study and presented alongside preliminary results in this paper. The use of this imaging modality provides a non-invasive and efficient method to analyze and understand HHT lesions.

SCIENTIFIC REPORTS (2022)

Article Clinical Neurology

Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease

Sharbel G. Romanos, Abhinav Srinath, Ying Li, Bingqing Xie, Chang Chen, Yan Li, Thomas Moore, Dehua Bi, Je Yeong Sone, Rhonda Lightle, Nick Hobson, Dongdong Zhang, Janne Koskimaki, Le Shen, Sara McCurdy, Catherine Chinhchu Lai, Agnieszka Stadnik, Kristina Piedad, Julian Carrion-Penagos, Abdallah Shkoukani, Daniel Snellings, Robert Shenkar, Dinanath Sulakhe, Yuan Ji, Miguel A. Lopez-Ramirez, Mark L. Kahn, Douglas A. Marchuk, Mark H. Ginsberg, Romuald Girard, Issam A. Awad

Summary: This study identifies homologous differentially expressed (DE) plasma miRNAs that can reflect germline mutations in familial cerebral cavernous malformation (CCM) in preclinical murine models and patients. The findings suggest the potential development of translatable circulating biomarkers for monitoring and restoring gene function in CCM and other diseases.

TRANSLATIONAL STROKE RESEARCH (2023)

Article Genetics & Heredity

A cross-species approach using an in vivo evaluation platform in mice demonstrates that sequence variation in human RABEP2 modulates ischemic stroke outcomes

Han Kyu Lee, Do Hoon Kwon, David L. Aylor, Douglas A. Marchuk

Summary: This study establishes an in vivo evaluation platform in mice and verifies that human RABEP2 can rescue the volume and collateral vessel phenotypes of mice with ischemic stroke. Additionally, it identifies damaging coding variants that affect the function of RABEP2, expanding the potential targets for ischemic stroke therapeutics development.

AMERICAN JOURNAL OF HUMAN GENETICS (2022)

Article Cardiac & Cardiovascular Systems

Cardiac Troponin I-Interacting Kinase Affects Cardiomyocyte S-Phase Activity but Not Cardiomyocyte Proliferation

Sean P. Reuter, Mark H. Soonpaa, Dorothy Field, Ed Simpson, Michael Rubart-von der Lohe, Han Kyu Lee, Arthi Sridhar, Stephanie M. Ware, Nick Green, Xiaochun Li, Susan Ofner, Douglas A. Marchuk, Kai C. Wollert, Loren J. Field

Summary: Genetic analysis found that Tnni3k expression increases cardiomyocyte S-phase activity after injury. This study may help guide the development of therapeutic interventions for cardiac regeneration.

CIRCULATION (2023)

Article Genetics & Heredity

Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia

K. P. Thompson, J. Sykes, P. Chandakkar, P. Marambaud, N. T. Vozoris, D. A. Marchuk, M. E. Faughnan

Summary: The study did not demonstrate the effectiveness of doxycycline as a treatment for epistaxis in patients with HHT, although hemoglobin levels were significantly higher during treatment. Secondary analyses may help guide future trials in HHT.

ORPHANET JOURNAL OF RARE DISEASES (2022)

Article Genetics & Heredity

Developmental expression of the Sturge-Weber syndrome-associated genetic mutation in Gnaq: a formal test of Happle's paradominant inheritance hypothesis

Sarah E. Wetzel-Strong, Francesca Galeffi, Christian Benavides, Mary Patrucco, Jessica L. Bullock, Carol J. Gallione, Han Kyu Lee, Douglas A. Marchuk

Summary: Sturge-Weber Syndrome (SWS) is a non-inherited syndrome characterized by vascular malformations in the face, leptomeninges, or choroid. A mouse model for SWS has been created using gene targeting to express the GNAQ p.R183Q mutation. These mice survive and show no obvious vascular defects, supporting the paradominant inheritance hypothesis for SWS and providing a model for studying postnatal phenotypes and developing therapies.

GENETICS (2023)

Review Chemistry, Medicinal

Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans

Matthew J. Hagan, Robert Shenkar, Abhinav Srinath, Sharbel G. Romanos, Agnieszka Stadnik, Mark L. Kahn, Douglas A. Marchuk, Romuald Girard, Issam A. Awad

Summary: Cerebral cavernous malformations (CCMs) are hemorrhagic neurovascular lesions that affect more than 1 million people in the United States. Rapamycin inhibits CCM development and bleeding in murine models. The appropriate dosage to modify disease phenotype remains unknown. Current approved indications by the U.S. Food and Drug Administration and clinicaltrials.gov were queried for rapamycin human dosing for various indications. In humans, low daily doses of <2 mg/day or trough level targets <15 ng/mL were typically used for benign indications akin to CCM disease, with relatively low complication rates. Higher oral doses in humans, used for organ rejection, result in higher complication rates. Oral dosing in mice, between 2 and 4 mg/kg/day, achieved blood trough levels in the 5-15 ng/mL range, a concentration likely to be targeted in human studies to treat CCM. Preclinical studies are needed utilizing dosing strategies which achieve blood levels corresponding to likely human dosimetry.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)

暂无数据